Aclarion, Inc. (ACON)
NASDAQ: ACON · Real-Time Price · USD
0.216
+0.027 (14.19%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Company Description
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States.
It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Aclarion, Inc.
Country | United States |
Founded | 2008 |
IPO Date | Apr 22, 2022 |
Industry | Health Information Services |
Sector | Healthcare |
Employees | 6 |
CEO | Brent Ness |
Contact Details
Address: 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 United States | |
Phone | 833 275 2266 |
Website | aclarion.com |
Stock Details
Ticker Symbol | ACON |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $4.35 |
CIK Code | 0001635077 |
CUSIP Number | 655187102 |
ISIN Number | US6551872012 |
Employer ID | 47-3324725 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Brent Ness | Chief Executive Officer, President and Director |
Dr. Jeffrey John Thramann M.D. | Executive Chairman |
John Lorbiecki | Chief Financial Officer |
Ryan Bond | Chief Strategy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 15, 2024 | D | Notice of Exempt Offering of Securities |
Oct 11, 2024 | POS AM | Post-Effective amendments for registration statement |
Oct 11, 2024 | 8-K | Current Report |
Oct 1, 2024 | 8-K | Current Report |
Sep 24, 2024 | 8-K | Current Report |
Sep 24, 2024 | 424B5 | Filing |
Sep 23, 2024 | EFFECT | Notice of Effectiveness |
Sep 23, 2024 | 8-K | Current Report |
Sep 19, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
Sep 9, 2024 | POS AM | Post-Effective amendments for registration statement |